Overview

Goserelin 10.8mg Injection in Treatment of Advanced Prostate Cancer

Status:
Unknown status
Trial end date:
2020-11-01
Target enrollment:
Participant gender:
Summary
A two arm, multi centric, randomized, open label, parallel, two doses pharmacodynamics study in patients with advanced prostate cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Eurofarma Laboratorios S.A.
Treatments:
Goserelin